TY - CHAP M1 - Book, Section TI - Anti-Parkinson Drugs A1 - Keen, Brendan A1 - Sherman, Marian A2 - Freeman, Brian S. A2 - Berger, Jeffrey S. PY - 2016 T2 - Anesthesiology Core Review: Part Two Advanced Exam AB - Parkinson's disease (PD) affects 3% of the population older than 66 years of age; therefore, PD is encountered relatively commonly in clinical anesthesia practice. Symptoms include resting tremor, rigidity, akinesia, and postural instability. These symptoms are due to destruction of dopaminergic neurons in the substania nigra, a component of the basal ganglia. The basal ganglia relays motor signals from cortex to thalamus and brainstem nuclei. Loss of dopaminergic neurons increasingly activates basal ganglia inhibitory nuclei, thereby suppressing cortical motor signals and inhibiting brainstem locomotor areas. Such disturbances in signaling produce Parkinsonian symptoms. Pharmacologic agents treat PD symptoms, mostly through dopaminergic pathways. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessanesthesiology.mhmedical.com/content.aspx?aid=1135739028 ER -